Prevenar 13®

The full indication for Prevenar 13® is active immunisation for the prevention of:

Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age. 
Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults ≥18 years of age and the elderly. 

Prevenar 13® helps protect against the following pneumococcal serogroups: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F 1

Prevenar 13® can be used within license to help protect people aged 6 weeks and above from invasive pneumococcal disease and pneumonia.1


Prevenar 13® is the recommended vaccine for the pneumococcal Primary Childhood Immunisation schedule.2

Recommended schedule 1,3 

The use of Prevenar 13 should be determined on the basis of official recommendations taking into consideration the risk of invasive disease and pneumonia in different age groups, underlying comorbidities as well as the variability of serotype epidemiology in different geographical areas. 1

The NIAC recommended schedule for Primary and booster vaccination consists of 3 doses at 2, 6 and 13 months of age.3


Prevenar 13 will only protect against Streptococcus pneumoniae serotypes included in the vaccine, and will not protect against other microorganisms that cause invasive disease, pneumonia, or otitis media. 1 Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have a reduced antibody response to Prevenar 13®.1


  1. Prevenar 13® Summary of Product Characteristics.  November 2020
  2. HSE Primary Childhood Immunisation Schedule. Available at: Last Accessed: February 2022
  3. NIAC Guidelines Chapter 16: Pneumococcal Infection


Legal Category: S1A

PP-PNA-IRL-0012   Preparation Date: March 2022